Menu
The promise of personalized healthcare rests on precise disease biosignatures.
Our lead infectious disease program harnesses extracellular vesicles (EVs) to be the first non-laboratory test to cover all stages of HIV infection.
Our EV-PSA prostate cancer screening test has the potential to dramatically increase the diagnostic predictivity of PSA to discriminate between benign and malignant conditions.
Our proprietary platform harnesses the unique communication in extracellular vesicle (EV) proteins, nucleic acids, and lipids for simple, point-of-care tests.
We use the platform for our pipeline and to partner with others on their proprietary tests for infectious disease, immune and metabolic monitoring, and cancer.